INDEX 05 / REFERENCES
CJC-1295 References
Every CJC-1295 citation referenced across this online edition — Phase 1 studies, preclinical work, regulatory documents, and review articles. Sortable by year, author, and trial phase.
Index 05 / Cited literature
Cited literature
The references below correspond to the inline citation markers used across this online edition. CJC-1295 has a small but specific clinical record — two published Phase 1 studies, one terminated Phase 2 trial, supporting preclinical work, and the regulatory documents that frame the compound's current status. Every numerical claim in the body pages of this site maps to one or more entries below.
DOI and PubMed links are provided where available. The reference table is sortable by year, journal, and source type. The full bibliographic record is preserved verbatim from the underlying research file; no citation is paraphrased.
| No. | Citation | Year | Source |
|---|---|---|---|
| 1 | Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. | 2005 | DOI · PMID |
| 2 | Coy DH, et al. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. Journal of Clinical Endocrinology and Metabolism. 1994. | 1994 | PMID |
| 3 | Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. | 2006 | DOI · PMID |
| 4 | Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. | 2006 | DOI · PMID |
| 5 | aidsmap editorial team. Lipodystrophy study halted after patient death (news report on ConjuChem CJC-1295 Phase 2 trial NCT00267527). aidsmap (NAM Publications). 2006. | 2006 | Link |
| 6 | FDA. Section 503A Category 2 removal of CJC-1295 and ipamorelin acetate. FDA Federal Register / Docket FDA-2024-N-4777. 2024. | 2024 | Link |
| 7 | World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA Prohibited List. 2024. | 2024 | Link |
| 8 | Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290-E1294. | 2006 | DOI · PMID |
| 9 | ConjuChem Biotechnologies. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527). ClinicalTrials.gov. 2005. | 2005 | Link |
| 10 | Wikipedia editors (citing primary literature on D-Ala2 substitution kinetics). Modified GRF (1-29) - chemical and pharmacological description. 2024. | 2024 | Link |
| 11 | Bagno LL, Kanashiro-Takeuchi RM, Suncion VY, et al. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. Journal of the American Heart Association. 2015. | 2015 | DOI |
| 12 | Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. | 1998 | DOI |
| 13 | Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (route-of-administration record). Journal of Clinical Endocrinology and Metabolism. 2006. | 2006 | DOI · PMID |
| 14 | ConjuChem Biotechnologies (legacy product documentation, summarized in regulatory filings). Modified GRF (1-29) and CJC-1295 handling — research-use product literature. FDA Docket FDA-2024-N-4777-0002 attachment 7. 2024. | 2024 | Link |
| 15 | Vijayakumar A, et al. The fascinating interplay between growth hormone, insulin-like growth factor-1, and insulin. Endocrinology and Metabolism (Korea). 2024. | 2024 | DOI |
| 16 | FDA. Section 503A Category 2 removal of CJC-1295 and ipamorelin acetate, effective 27 September 2024. FDA Federal Register / Docket FDA-2024-N-4777. 2024. | 2024 | Link |
| 17 | Traynor K. FDA approves tesamorelin for HIV-related lipodystrophy. American Journal of Health-System Pharmacy. 2010;67(24):2082. | 2010 | Link |
| 18 | Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010;2(11-12). | 2010 | DOI · PMID |
| 19 | Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021. | 2021 | DOI |
| 20 | Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Annals of Internal Medicine. 1996. | 1996 | PMID |